Article
Winter Park, FL-LaserSight Inc. and a third-party buyer have ended an agreement to buy LaserSight's AstraMax technology over an exclusivity dispute.
OKYO Pharma’s lead asset OK-101 receives United States Adopted Name “urcosimod”
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Study finds human breast milk may aid in corneal wound healing
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Retinoblastoma care goes digital: insights from two decades of teleophthalmology
Qlaris Bio announces positive data from 2 clinical trials investigating QLS-111 in patients with primary open angle glaucoma and ocular hypertension